信達生物(01801.HK):將收回IBI-305的相關權益
格隆匯5月6日丨信達生物(01801.HK)發佈公吿,2020年1月14日,公司與Coherus BioSciences, Inc.簽訂了一項合作協議,授予Coherus公司的貝伐珠單抗生物類似藥(IBI-305)在美國和加拿大的商業化權益。
作為本項協議的最新進展,公司與Coherus決定終止該項協議,公司將收回IBI-305的相關權益。本次商業決策是在評估貝伐珠單抗生物類似藥北美市場動態以及受疫情持續影響開發延誤後做出的。公司對該藥物的療效及安全性充滿信心,本決定不影響該產品於其它地區的安排。根據協議條款,公司將收回IBI-305於美國和加拿大的商業化權益。雙方將共同配合權益過渡。
與海外公司的合作為公司產品管線的海外開發提供了寶貴經驗及更多元化的數據。公司認為該項協議的變更影響非常有限,且不會改變公司全球創新和全球化戰略的長期前景。公司將繼續堅定推行公司戰略,加速向全球生物製藥公司的轉型,帶動公司持續發展,將高質量的創新藥物帶向全世界的患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.